Rx Prescripttion Only-YMYL Medical Content

Eudaxen 50 mg

Diazoxide 50 mg tablets – Everest Pharmaceutical Ltd.

Approved for oral use in adults and children with intractable hypoglycemia caused by hyperinsulinism — including congenital hyperinsulinism (CHI), insulinoma (functional islet cell tumors), leucine-sensitive hypoglycemia, islet cell hyperplasia, and extra-pancreatic tumors causing excess insulin secretion.

~71%

Pooled response rate in hyperinsulinism across cohort studies (meta-analysis)

Only

FDA-approved oral drug for hyperinsulinemic hypoglycemia — in use since 1973

K-ATP

Mechanism: opens potassium channels in beta cells, suppressing insulin secretion

2–3×

Daily divided oral dosing — dose calculated by body weight

Confirm the cause of hypoglycemia

Diazoxide works by suppressing insulin secretion — so it is only effective where excess insulin is the cause. Non-hyperinsulinism causes of low blood sugar (e.g., liver disease, adrenal insufficiency) will not respond and require different treatment.

Identify the underlying condition driving hyperinsulinism

Congenital hyperinsulinism (CHI), insulinoma, islet cell hyperplasia, or an insulin-secreting tumor — the specific diagnosis affects both response likelihood and whether diazoxide is first-line or a bridge to surgery.

Assess cardiovascular and fluid retention risk

Diazoxide causes sodium and water retention, which can worsen heart failure, pulmonary hypertension (especially in neonates and infants), or renal insufficiency — these must be reviewed before starting.

Discuss goals of care and need for a diuretic

Weigh blood glucose stabilization benefit against salt/water retention, which often requires concurrent use of a diuretic (such as furosemide) to manage fluid balance throughout treatment.

Important safety information: Diazoxide causes sodium and water retention in most patients, potentially leading to edema, heart failure, or pulmonary hypertension — particularly dangerous in neonates and infants with pre-existing heart or lung conditions. In 2015, the FDA issued a specific warning about pulmonary hypertension in infants treated with diazoxide, advising close monitoring for signs of respiratory distress and immediate discontinuation if pulmonary hypertension develops. Blood pressure and blood glucose must be monitored regularly throughout treatment.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Diazoxide is the only approved oral treatment we have for hyperinsulinemic hypoglycemia, and for patients who respond — roughly 70% — it can stabilize blood glucose and prevent the neurodevelopmental damage that repeated hypoglycemia causes. The fluid retention and pulmonary hypertension risks, especially in neonates, mean we never start it without close monitoring and a clear plan for managing those complications.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my endocrinologist about starting diazoxide for hyperinsulinism?

Here are key questions to bring to your endocrinologist — because diazoxide affects both blood sugar and fluid balance, and because it’s used in patients ranging from newborns to adults, the questions naturally span those two distinct risk areas.

Before confirming diazoxide as your treatment

Has it been confirmed that my hypoglycemia is caused by excess insulin specifically — and not another cause like liver disease, adrenal insufficiency, or a different hormonal problem?
What is the underlying condition driving the hyperinsulinism — congenital hyperinsulinism, insulinoma, islet cell hyperplasia, or something else — and does that affect how likely diazoxide is to work for me?
Is diazoxide being used as a long-term treatment, or as a bridge while other options (like surgery) are being evaluated?
What happens if diazoxide doesn’t work — what would the next step be?

About fluid retention — the most universal concern

Will I need a diuretic (like furosemide) alongside diazoxide to manage fluid retention, and if so, how will that be dosed and monitored?
What signs of fluid retention — swelling in the legs or ankles, sudden weight gain, breathlessness — should prompt me to call rather than wait for my next appointment?
Do I have any existing heart, lung, or kidney condition that changes how closely fluid balance needs to be monitored?

For infants and neonates — the pulmonary hypertension warning

What are the early signs of pulmonary hypertension in my baby — flaring nostrils, grunting, rapid breathing, difficulty feeding, a bluish tint to the lips — and what do I do if I notice them?
Does my baby have any risk factors (respiratory distress syndrome, heart abnormalities, premature birth) that make pulmonary hypertension more likely?
How often will cardiac and respiratory status be monitored, especially in the first weeks of treatment?
If pulmonary hypertension develops, how quickly would diazoxide be stopped, and what would happen to blood sugar control at that point?

About blood glucose monitoring

How often should blood sugar be checked at home, and what glucose level threshold should prompt urgent action?
What are the signs of hypoglycemia that I (or my child’s caregivers) need to recognize and respond to immediately — shakiness, sweating, confusion, seizure, loss of consciousness?
What is the emergency plan if blood sugar drops severely despite being on diazoxide?

About dosing

How is the dose calculated, and what is my (or my child’s) starting dose?
How many times per day should it be taken, and does timing relative to meals matter?
What happens if a dose is missed?
How will we know if the dose needs to be increased or decreased over time?

About blood count and other monitoring

Will blood counts be checked regularly, given the risk of neutropenia and thrombocytopenia?
What symptoms — unusual bruising, frequent infections, prolonged bleeding — should prompt a blood count check between scheduled visits?
Will uric acid levels be monitored, given the hyperuricemia risk?

About other medications and interactions

Are there any medications I (or my child) currently take that interact with diazoxide — particularly blood pressure medications, diuretics, or anticoagulants?
Since diazoxide can raise blood sugar, does this need to be considered alongside any other conditions or medications?

About the cosmetic side effect — hypertrichosis

How common is excess hair growth on this medication, and does it reverse when treatment is stopped?
Is this expected in all patients or more common in certain age groups or doses?

About the longer road

If this is for congenital hyperinsulinism in a child — is there a point at which the condition might improve or resolve, allowing diazoxide to eventually be tapered or stopped?
For insulinoma — is surgery still being considered, and does starting diazoxide affect the timeline for that decision?
How often will response be formally reassessed, and what does “not responding” look like in terms of blood glucose patterns?

A practical tip: Because diazoxide affects both blood sugar and blood pressure simultaneously, and because the monitoring requirements span endocrinology, cardiology (especially in infants), and sometimes nephrology, it’s worth asking your endocrinologist upfront which other specialists should be looped in — particularly if your child has any heart or lung history. Having a written emergency action plan for severe hypoglycemia is also worth requesting specifically, so that everyone caring for the patient (school, childcare, other family members) knows exactly what to do.

compare with other therapies

Compare diazoxide vs octreotide for treating congenital hyperinsulinism

This comparison is one of the most clinically important decisions in congenital hyperinsulinism (CHI) management — and unlike many of our earlier comparisons, these two drugs are often used sequentially rather than interchangeably, with the choice between them driven largely by whether diazoxide works at all for a given patient’s genetic subtype.

The fundamental difference in how they work

	Diazoxide	Octreotide
Drug class	K-ATP channel activator	Somatostatin analog
Mechanism	Opens K-ATP channels in pancreatic beta cells → hyperpolarizes the cell → suppresses insulin release	Binds somatostatin receptors on beta cells → broadly suppresses insulin secretion through a different pathway
Route	Oral tablet	Subcutaneous injection (or continuous IV/SC infusion in severe cases)
Approved for CHI	Yes — only FDA-approved oral drug for hyperinsulinemic hypoglycemia	Off-label for CHI (approved for acromegaly and carcinoid tumors, but widely used in CHI as second-line)

This mechanism difference is critical: diazoxide works by activating the K-ATP channel — but in the most common severe forms of CHI (recessive ABCC8 or KCNJ11 mutations), the K-ATP channel itself is defective or absent. You cannot activate a channel that doesn’t function properly, which is why diazoxide typically fails in these genetic subtypes and octreotide becomes necessary.

Genetic subtype — the main factor determining which drug works

Genetic subtype	Diazoxide response	Octreotide response
Dominant ABCC8/KCNJ11 mutations	Usually responsive	May not be needed
Recessive ABCC8/KCNJ11 mutations	Usually unresponsive	Often used as bridge to surgery
KATP-independent forms (GDH, GCK, HNF4A mutations)	Variable — often responsive	Variable
Focal CHI (any mutation)	Often unresponsive	Used as bridge to surgery
Diffuse CHI (recessive KATP mutations)	Usually unresponsive	Used to manage glucose while awaiting surgery

The practical workflow in most CHI centers is: try diazoxide first (since it’s oral and easier to manage at home), assess response over 5–7 days, and if blood glucose targets aren’t achieved, move to octreotide — often while genetic testing results are still pending.

Administration — a major quality-of-life difference

	Diazoxide	Octreotide
How given	Oral tablets or suspension, 2–3 times daily	Subcutaneous injection, typically 3–4 times daily — or continuous subcutaneous/IV infusion in hospital
At home	Yes — once stabilized	Injections can be taught to parents, but more burdensome than oral dosing
Long-acting version	No oral equivalent	Long-acting release (LAR) monthly injection available (Sandostatin LAR) — sometimes used for longer-term management in older children or adults

The injection burden of octreotide — multiple times daily in a newborn or infant — is genuinely significant for families, which is one reason diazoxide is always tried first when there’s any reasonable chance of response.

Side effect comparison

	Diazoxide	Octreotide
Most distinctive risk	Sodium/water retention, pulmonary hypertension (neonates)	Necrotizing enterocolitis risk (neonates) — a serious bowel complication
GI effects	Nausea (early), anorexia	Diarrhea, abdominal discomfort, fat malabsorption
Metabolic effects	Hyperuricemia	Reduced growth hormone (in children) — potential growth concerns with long-term use
Gallstones	Not associated	Associated — somatostatin analogs reduce bile flow
Blood counts	Neutropenia, thrombocytopenia	Less prominent
Hair growth	Hypertrichosis — very common	Not associated
Blood sugar overshoot	Hyperglycemia if dose too high	Hypoglycemia can paradoxically worsen if dosing is imprecise

Octreotide’s necrotizing enterocolitis risk in neonates is a serious concern that has made some centers cautious about its use in very young infants, particularly those who are premature or feeding enterally. This is one reason octreotide is often given as a continuous infusion in hospital before transitioning families to home subcutaneous injections.

Efficacy — in context

For diazoxide-responsive CHI, response rates cluster around the 70% range pooled across cohort studies — meaning roughly 3 in 10 patients who are candidates for diazoxide still don’t achieve adequate glucose control with it.

For octreotide in diazoxide-unresponsive CHI, it’s typically understood as a temporizing measure rather than a definitive treatment — it can improve glucose control and reduce IV glucose requirements while families and surgical teams prepare for a more definitive intervention (pancreatectomy), rather than achieving lasting remission on its own in severe cases.

How the treatment pathway typically unfolds

For most newly diagnosed CHI patients, the pathway looks something like this:

First, diazoxide is trialed — this is the standard first-line approach given its oral route and established safety profile. Genetic testing is sent simultaneously (though results may take weeks). If blood glucose stabilizes on diazoxide, the patient can often be managed at home on oral medication.

If diazoxide fails — either no response within 5–7 days, or the genetic subtype is already known to be diazoxide-unresponsive — octreotide is started, often initially in hospital as a continuous infusion. This buys time for further workup including an [18F]-DOPA PET scan to distinguish focal from diffuse disease, since focal CHI can potentially be cured by limited surgical resection, while diffuse CHI typically requires near-total pancreatectomy.

Bottom line

Diazoxide and octreotide aren’t really alternatives in the way most of our comparisons have been — they’re sequential tools in a treatment algorithm driven by genetic subtype and diazoxide response. Diazoxide is always tried first for its oral convenience and established profile; octreotide steps in when diazoxide fails, typically as a bridge to surgery in the more severe, genetically-defined cases where the K-ATP channel itself is the problem. The surgical question — whether and what kind of pancreatectomy — runs in parallel with both drug decisions and ultimately determines long-term management for the diazoxide-unresponsive population.

How does testing work

How is congenital hyperinsulinism diagnosed and what genetic testing is involved?

Congenital hyperinsulinism (CHI) diagnosis combines clinical biochemistry, imaging, and genetic testing — and unlike the mutation testing we’ve discussed throughout this conversation (where a known mutation opens the door to a specific drug), genetic testing in CHI serves multiple purposes simultaneously: confirming diagnosis, predicting diazoxide response, and guiding surgical planning.

The clinical presentation that triggers investigation

CHI typically presents in the newborn period or early infancy with recurrent, severe hypoglycemia that is disproportionate to fasting duration — meaning blood sugar drops faster and lower than it should, even with normal or frequent feeds. The key biochemical signature at the time of a low blood sugar episode is:

Low blood glucose (typically below 2.5–3.0 mmol/L)
Inappropriately elevated or detectable insulin level (insulin should be suppressed to near-zero during hypoglycemia — any measurable level is abnormal in this context)
Low ketones and low free fatty acids (because insulin suppresses fat breakdown, the body can’t generate its normal alternative fuel sources)
Elevated C-peptide (confirms endogenous insulin secretion rather than accidental or deliberate insulin administration)

This constellation — low glucose, detectable insulin, suppressed ketones and fatty acids — is called hyperinsulinemic hypoglycemia and is the biochemical definition of the condition.

The diagnostic “gold standard” — the glucagon stimulation test

During a documented hypoglycemic episode, an intravenous glucagon dose is given. A significant rise in blood glucose in response to glucagon confirms that glycogen stores are intact and insulin has been preventing their release — this is the hallmark response of hyperinsulinism. Without this test, some centers use a controlled fasting study under close monitoring to provoke and document a hypoglycemic episode with simultaneous critical blood and urine samples.

Biochemical tests used

At the time of hypoglycemia, a “critical sample” is drawn, typically including:

Blood glucose (laboratory-confirmed, not just glucometer)
Insulin and C-peptide
Cortisol and growth hormone (to rule out other hormonal causes)
Beta-hydroxybutyrate (ketone marker)
Free fatty acids
Ammonia (elevated in GDH mutation subtype — an important clue)
Urine organic acids (to rule out metabolic disorders)

Genetic testing — which genes and what they mean

CHI is genetically heterogeneous — at least 12 genes have been implicated, but the most clinically important are:

ABCC8 and KCNJ11 — these encode the two subunits of the K-ATP channel (SUR1 and Kir6.2 respectively) and together account for the majority of severe, diazoxide-unresponsive CHI. The inheritance pattern matters enormously here:

Recessive mutations in ABCC8/KCNJ11 cause diffuse or focal disease and are typically diazoxide-unresponsive (because the K-ATP channel is non-functional)
Dominant mutations in ABCC8/KCNJ11 tend to cause milder, diazoxide-responsive disease

GLUD1 — encodes glutamate dehydrogenase (GDH); mutations cause the hyperinsulinism-hyperammonemia (HI/HA) syndrome, which is characteristically diazoxide-responsive and associated with elevated ammonia levels on the critical sample

GCK — activating mutations cause hyperactivity of glucokinase, leading to excessive insulin secretion; generally diazoxide-responsive but variable

HNF4A and HNF1A — transcription factor mutations; often diazoxide-responsive, but HNF4A mutations can cause a transient form that may resolve in childhood

HADH, UCP2, MCM4, PMM2 and others — rarer subtypes, each with distinct metabolic features

How genetic testing is done

Most specialist centers now use next-generation sequencing (NGS) gene panels covering all known CHI genes simultaneously — this has largely replaced sequential single-gene testing and can return results in 2–4 weeks.

In cases where panel testing is negative but the clinical picture strongly suggests CHI, whole exome sequencing (WES) or whole genome sequencing (WGS) may identify novel mutations in previously unrecognized genes.

Parental testing is often performed alongside the proband (the affected child), because:

Identifying whether a mutation is inherited (and from which parent) helps determine whether it’s recessive or dominant
For ABCC8/KCNJ11 specifically, parental testing helps distinguish diffuse from focal disease (see below)

The focal vs diffuse distinction — why it’s critical for surgery

This is where CHI differs most from the mutation testing we’ve discussed in oncology:

Diffuse CHI — all beta cells throughout the pancreas are abnormal, typically caused by recessive biallelic ABCC8/KCNJ11 mutations. Surgical treatment requires near-total pancreatectomy (removing 95–98% of the pancreas), which carries a high long-term risk of diabetes.

Focal CHI — a small cluster of abnormal beta cells in one localized area of the pancreas, caused by a somatic loss of the maternal ABCC8/KCNJ11 allele in a small region, on top of a germline paternal mutation. Surgical removal of just the focal lesion can be curative with minimal pancreatic damage.

Genetically, focal disease is suspected when a child has a heterozygous paternal ABCC8 or KCNJ11 mutation — because somatic loss of the maternal copy in a focal region explains why only one parent’s mutation is identified on standard sequencing.

Imaging — the [18F]-DOPA PET scan

Once diazoxide failure is established and genetics suggest a possible focal lesion, a [18F]-DOPA PET scan (using a specialized radiotracer taken up by pancreatic beta cells) is done to try to localize a focal lesion before surgery. This scan is only available at a small number of specialist CHI centers worldwide, which is one reason CHI surgery should be performed at high-volume specialist centers rather than general pediatric surgical units.

Timeline of the diagnostic workup

Step	Timing
Critical sample + glucagon test	At first documented hypoglycemic episode
Diazoxide trial	Started within days of diagnosis confirmation
Genetic panel (NGS)	Sent simultaneously, results in 2–4 weeks
Parental genetic testing	Once proband mutation identified
[18F]-DOPA PET scan	If diazoxide fails and focal disease suspected
Surgical decision	After PET scan localization (focal) or after confirming diffuse disease

A practical nuance

Because genetic results typically take weeks and clinical management (diazoxide trial, octreotide if needed, glucose infusion requirements) can’t wait that long, most specialist centers make initial treatment decisions based on clinical response and interim biochemical markers (like ammonia level suggesting GDH mutation), with genetic results then refining or confirming the plan. The genetics don’t determine immediate treatment — they refine longer-term surgical planning and predict diazoxide response probability.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.